-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Immunotherapy with Cells

Program: Education Program
Session: Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma
Hematology Disease Topics & Pathways:
Biological, CRS, neurotoxicity, Diseases, Lymphoma (any), Therapies, CAR-Ts, Adverse Events, gene therapy, Lymphoid Malignancies
Monday, December 7, 2020, 6:55 AM-7:00 AM

David L. Porter, MD

Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA; Cell Therapy and Transplant, Abramson Cancer Center and Hematology-Oncology Division, University of Pennsylvania, Philadelphia, PA

Disclosures: Porter: Novartis: Honoraria, Other: Advisory board, Patents & Royalties: CAR T cells for CD19+ malignancies, Research Funding; Tmunity: Patents & Royalties; American Board of Internal Medicine: Other: Member, exam writing committee (end date Oct 2019); Kite/Gilead: Other: Advisory board; Incyte: Other: Advisory board; Adicet bio: Other: Advisory board; Glenmark: Other: Advisory board; Genentech/Roche: Current equity holder in publicly-traded company, Other: Spouse employment (ended Sept 2020); her salary includes stock/options; Janssen: Other: Advisory board; National Marrow Donor Program: Membership on an entity's Board of Directors or advisory committees.

OffLabel Disclosure:

<< Previous Presentation | Next Presentation